<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970746</url>
  </required_header>
  <id_info>
    <org_study_id>PDC-LUNG-101</org_study_id>
    <secondary_id>2018-002382-19</secondary_id>
    <nct_id>NCT03970746</nct_id>
  </id_info>
  <brief_title>Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC</brief_title>
  <official_title>An Open-label, Dose-escalation, Phase I/II Study to Assess the Safety, the Tolerability, the Immunogenicity and the Preliminary Clinical Activity of the Therapeutic Cancer Vaccine, PDC*lung01, Associated or Not With Anti-PD-1 Treatment in Patients With Non-small-cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PDC*line Pharma SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PDC*line Pharma SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PDC-LUNG-101 trial is an open-label, dose-escalation, phase I/II study to assess the safety,&#xD;
      the tolerability, the immunogenicity and the preliminary clinical activity of the therapeutic&#xD;
      cancer vaccine, PDC*lung01, associated or not with anti-PD-1 treatment in patients with&#xD;
      non-small-cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The therapeutic cancer vaccine, PDC*lung01 will be administered at two dose levels (low dose&#xD;
      (LD) and high dose (HD)), as single agent or during maintenance treatment by pemetrexed (for&#xD;
      adenocarcinomas in Cohorts A1 and A2) or added to the SoC (cohorts B1 and B2) i.e. anti-PD-1.&#xD;
&#xD;
      In cohorts A1 (low dose cohort) and A2 (high dose cohort), NSCLC patients will be treated at&#xD;
      each of the six PDC*lung01 treatment visits with low dose/high dose administered successively&#xD;
      by subcutaneous and then by intravenous route.&#xD;
&#xD;
      In cohort B1 and B2, the first PDC*lung01 injection will start within 48 hours after the&#xD;
      first infusion of anti-PD-1. The fourth PDC*lung01 injection will occur within 48 hours after&#xD;
      the infusion of the second cycle of anti-PD-1.&#xD;
&#xD;
      For each patient, the study will be divided into three consecutive parts:&#xD;
&#xD;
        -  Pre-screening (for HLA-A*02:01 positivity), only patients with positive HLA-A*02:01&#xD;
           status will be proposed to be screened.&#xD;
&#xD;
        -  Active period comprising a screening period, a treatment period (visits V1 to V6, during&#xD;
           which the patient receives PDC*lung01 vaccine, at each visit) and an end-of-treatment&#xD;
           (EoT) visit (V7, 4 weeks after the last injection),&#xD;
&#xD;
        -  Follow-up period which starts after the EoT visit and lasts up to two years after the&#xD;
           first IMP administration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 10, 2019</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of dose-limiting toxicities (DLT) related to the administration of PDC*lung01</measure>
    <time_frame>Up to one week after the last injection (Day 42)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events (SAEs) and adverse events (AEs), deemed as related to the association of PDC*lung01 and the anti-PD-1 therapy</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of serious adverse events (SAEs) and adverse events (AEs)</measure>
    <time_frame>Up to Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of anti-HLA class I and II antibodies in the serum</measure>
    <time_frame>Screening, Day 35 and Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ex vivo detection and characterization of CD8+ T cells against tumor antigens borne by PDC*lung01, using flow cytometry</measure>
    <time_frame>Screening, Day 35 and Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (according to RECIST version 1.1 for cohorts A1/A2 and iRECIST for cohorts B1/B2)</measure>
    <time_frame>Day 63</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>9 months from the first day of platinum-based or anti-PD-1 antibody administration</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDC*lung01 Low Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDC*lung01 High Dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDC*lung01 Low Dose added to SoC, i.e., anti-PD-1 treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PDC*lung01 High Dose added to SoC, i.e., anti-PD-1 treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PDC*lung01</intervention_name>
    <description>PDC*lung01 includes, in similar proportion, seven active agents, made of irradiated human plasmacytoid dendritic cells (PDC) loaded separately with a distinct synthetic peptide encoded by a lung tumor antigen, namely NY-ESO-1, MAGE-A3, MAGEA4, Multi-MAGE (an epitope common to several MAGE-A antigens), SURVIVN, MUC1 or a peptide derived from the Melan-A antigen.</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keytruda Injectable Product</intervention_name>
    <description>The intention and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%) must have been made by the investigator before and regardless of the patient's participation in the study.</description>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
    <other_name>Pembrolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alimta Injectable Product</intervention_name>
    <description>For patients with non-squamous NSCLC included in Cohorts A1 and A2, maintenance by pemetrexed (IV every 3 weeks) can be administered according to SoC.</description>
    <arm_group_label>Cohort A1</arm_group_label>
    <arm_group_label>Cohort A2</arm_group_label>
    <other_name>Pemetrexed</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Pre-screening:&#xD;
&#xD;
        Documented HLA-A*02:01 positivity after the patient has provided written informed consent.&#xD;
&#xD;
        Only patients showing a documented positive result in pre-screening will be allowed to&#xD;
        enter the screening period.&#xD;
&#xD;
        Screening:&#xD;
&#xD;
          1. Patients with histologically proven, or cytologically proven (allowed only for&#xD;
             patients recruited in cohorts A1/A2), non-small-cell lung cancer (NSCLC). The stage of&#xD;
             the disease is evaluated according to the classification of the American Joint&#xD;
             Committee on Cancer, 8th edition (see Section 25.1)&#xD;
&#xD;
             a. For the dose-escalation phase (Cohorts A1 and A2): a wash-out period of at least 4&#xD;
             weeks after administration of the last cycle of platinum-based chemotherapy is&#xD;
             required.&#xD;
&#xD;
             (i) Stage IIa/IIb/IIIa NSCLC following surgery and, if applicable, following adjuvant&#xD;
             platinum-based chemotherapy, or (ii) Stage IV histologically or cytologically&#xD;
             confirmed case of epidermoid (squamous) NSCLC following 4 courses of platinum-based&#xD;
             therapy, if targeted treatment options were not indicated or (iii) Stage IV&#xD;
             histologically or cytologically confirmed case of adenocarcinoma (non-squamous) lung&#xD;
             cancer NSCLC following 4 to 6 courses cycles of pemetrexed and platinum combination if&#xD;
             targeted treatment options were not indicated, (iv) Populations (ii) and (iii) who&#xD;
             have stopped prematurely chemotherapy, after at least 2 cycles of platinum-based&#xD;
             therapy, for any reason, AND do present with a documented stable disease or complete&#xD;
             response.&#xD;
&#xD;
             b. For the anti-PD-1 immunotherapy (Cohorts B1 and B2): The patient has first-line&#xD;
             metastatic stage IV NSCLC measurable disease and is starting anti-PD-1. The intention&#xD;
             and decision to prescribe the anti-PD-1 monotherapy as SoC (TPS≥50%), assuming no&#xD;
             targeted mutation detected, following standard NGS testing, if applicable, and thus no&#xD;
             targeted treatment option is indicated, must have been made by the investigator before&#xD;
             and regardless of the patient's participation in the study.&#xD;
&#xD;
          2. ECOG performance status 0 or 1.&#xD;
&#xD;
          3. Adequate renal and hepatic function as defined below:&#xD;
&#xD;
               -  Serum creatinine clearance &gt; 50 mL/min (Cockcroft-Gault formula)&#xD;
&#xD;
               -  Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 times ULN (up&#xD;
                  to 5 times ULN are allowed in case of presence of liver metastases).&#xD;
&#xD;
          4. Adequate haematological function as defined below:&#xD;
&#xD;
               -  Platelet count ≥ 70 x 10⁹/L;&#xD;
&#xD;
               -  White blood cell count ≥ 2.5 x 10⁹/L with&#xD;
&#xD;
               -  lymphocytes ≥ 1 x 10⁹/L, among which ≥ 10 % of CD8+ T cells and&#xD;
&#xD;
               -  absolute neutrophil count ≥ 1.5 x 10⁹/L;&#xD;
&#xD;
               -  Haemoglobin ≥ 90 g/L&#xD;
&#xD;
          5. Patient willing and able to provide a baseline blood sample for leucocyte enumeration,&#xD;
             cellular allogeneic response and immune-monitoring of 100 ml in total (in one or two&#xD;
             samplings).&#xD;
&#xD;
          6. For patients with brain metastases:&#xD;
&#xD;
               -  Central nervous system metastases are not symptomatic and have been treated,&#xD;
&#xD;
               -  In addition, subjects must be either off corticosteroids, or on a stable or&#xD;
                  decreasing dose of ≤10mg daily prednisone (or equivalent) during at least 2 weeks&#xD;
                  before baseline.&#xD;
&#xD;
          7. For female patients without child-bearing potential: a documentation of tubal ligation&#xD;
             or hysterectomy, ovariectomy or a post-menopausal status is available.&#xD;
&#xD;
             For female patients of child-bearing potential: a negative serum pregnancy test at&#xD;
             screening is required. The patient agrees to practiceuse a &quot;dual method&quot;highly&#xD;
             effective contraception method from signing informed consent form (screening),&#xD;
             throughout the study treatment period with PDC*lung01 and for at least 28 days after&#xD;
             the last administration of PDC*lung01.&#xD;
&#xD;
             For female patients receiving Pemetrexed in cohorts A1/A2 concomitantly with&#xD;
             PDC*lung01, according to corresponding SmPC, it is required to use effective&#xD;
             contraception during treatment with pemetrexed.&#xD;
&#xD;
             For female patients receiving Pembrolizumab in cohorts B1/B2 concomitantly with&#xD;
             PDC*lung01, according to corresponding SmPC, it is required to use an effective method&#xD;
             of contraception up to 4 months thereafter.&#xD;
&#xD;
             A woman is considered of childbearing potential (WOCBP), i.e. fertile, following&#xD;
             menarche and until becoming post-menopausal unless permanently sterile. Permanent&#xD;
             sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral&#xD;
             oophorectomy.&#xD;
&#xD;
             A postmenopausal state is defined as no menses for 12 months without an alternative&#xD;
             medical cause.&#xD;
&#xD;
             &quot;Highly effective&quot; contraceptive measures acceptable for the whole duration of the&#xD;
             study have been defined based on the CTFGs recommendations on contraception and are&#xD;
             the following:&#xD;
&#xD;
               -  Combined (estrogen and progestogen containing) hormonal contraception associated&#xD;
                  with inhibition of ovulation (oral, intravaginal, transdermal),&#xD;
&#xD;
               -  Progestogen-only hormonal contraception associated with inhibition of ovulation&#xD;
                  (oral, injectable, implantable).&#xD;
&#xD;
               -  Intrauterine device (IUD)&#xD;
&#xD;
               -  Intrauterine hormone-releasing system (IUS)&#xD;
&#xD;
               -  Monogamous relationship with a vasectomized partner. Partner must have been&#xD;
                  vasectomized for at least 6 months before the participant entered into the study&#xD;
&#xD;
               -  Abstinence or absence of sexual relations with men.&#xD;
&#xD;
          8. Males with reproductive potential should use barrier method of contraception (condom)&#xD;
             from signing informed consent form (screening) up to at least 28 days after the last&#xD;
             dose of PDC*lung01.&#xD;
&#xD;
             For male patients receiving Pemetrexed in cohorts A1/A2 concomitantly with PDC*lung01,&#xD;
             according to corresponding SmPC, it is required to use barrier method of contraception&#xD;
             up to 6 months thereafter.&#xD;
&#xD;
          9. In the Investigator's opinion, the patient is able and willing to comply with the&#xD;
             requirements of the study.&#xD;
&#xD;
         10. Patient willing and able to sign the study informed consent form before any&#xD;
             study-specific procedures are conducted.&#xD;
&#xD;
         11. Patient (male or female) is aged 18 years or above.&#xD;
&#xD;
         12. Specific for patients enrolled in France : Patient is affiliated to a health insurance&#xD;
             system.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Mixed small-cell and non-small-cell histological features.&#xD;
&#xD;
          2. Patient has documented evidence of EGFR mutation, ALK fusion or ROS1 fusion (according&#xD;
             to current ESMO clinical practice guidelines) or any mutation for which targeted&#xD;
             treatment options would be indicated, as per SoC.&#xD;
&#xD;
          3. Patient has received immunotherapy or any investigational drugs within 4 weeks before&#xD;
             the first PDC*lung01 dose.&#xD;
&#xD;
          4. Patient without brain metastasis is receiving systemic corticosteroids at a dose level&#xD;
             exceeding 10 mg/day (prednisone or equivalent) during the screening period&#xD;
             (administration by nasal spray, topical solution or oral inhaler is non-systemic and&#xD;
             is therefore allowed).&#xD;
&#xD;
          5. Patient has a medical history of cancer other than NSCLC, except the following: (i)&#xD;
             non-melanoma skin cancer with complete resection, (ii) in situ carcinoma of the&#xD;
             cervix, (iii) other cancer treated with no evidence of disease for at least five&#xD;
             years.&#xD;
&#xD;
          6. Patient presents at screening anti-HLA antibodies against HLA molecules expressed by&#xD;
             the PDC*line.&#xD;
&#xD;
          7. Known hepatitis B and/or C infection (testing not required).&#xD;
&#xD;
          8. Known positive for human immunodeficiency virus (HIV; testing not required).&#xD;
&#xD;
          9. Uncontrolled congestive heart failure or hypertension, unstable heart disease&#xD;
             (coronary artery disease with unstable angina or myocardial infarction within 6 months&#xD;
             of baseline) or uncontrolled ventricular arrhythmias at the time of enrolment in the&#xD;
             study (atrial fibrillation or flutter is acceptable).&#xD;
&#xD;
         10. Any history of splenectomy or splenic irradiation.&#xD;
&#xD;
         11. For female patients: pregnancy or lactation.&#xD;
&#xD;
         12. Any condition, including autoimmune or immunodeficiency active disease that, in the&#xD;
             opinion of the Investigator, would jeopardise patient's safety, or might compromise&#xD;
             the effect of the study drug or the assessment of the study result.&#xD;
&#xD;
         13. Specific for patients enrolled in France: Patient is under legal protection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Vansteenkiste, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>KU Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florence Renard</last_name>
    <phone>+32 (0) 474/910 183</phone>
    <email>f.renard@pdc-line-pharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grand Hôpital de Charleroi</name>
      <address>
        <city>Charleroi</city>
        <zip>6000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 71 10 47 08</phone>
    </contact>
    <investigator>
      <last_name>Benoit Colinet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristof Cuppens, MD</last_name>
      <email>Kristof.Cuppens@jessazh.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofie Derijcke, MD</last_name>
      <email>Sofie.derijcke@azgroeninge.be</email>
    </contact>
    <contact_backup>
      <last_name>Fem Deplus, Mr.</last_name>
      <email>Fem.deplus@azgroeninge.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University Hospitals KU Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 16 340643</phone>
    </contact>
    <investigator>
      <last_name>Johan Vansteenkiste, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège- Sart Tilman</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 43 66 82 50</phone>
    </contact>
    <investigator>
      <last_name>Anne Sibille, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta vzw</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingel Desmedts, MD</last_name>
      <email>ingel.demedts@azdelta.be</email>
    </contact>
    <contact_backup>
      <last_name>Melissa Masschelin, Mrs.</last_name>
      <email>Melissa.Masschelin@azdelta.be</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Nikolaas</name>
      <address>
        <city>Sint-Niklaas</city>
        <zip>9100</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Van de Kerkhove, MD</last_name>
      <email>Charlotte.VandeKerkhove@aznikolaas.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 76 76 70 32</phone>
    </contact>
    <investigator>
      <last_name>Denis Moro-Sibilot</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard, Centre de lutte contre le cancer</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 26 55 68 42</phone>
    </contact>
    <investigator>
      <last_name>Maurice Pérol</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Marseille, Centre d'essais précoces en cancérologie de Marseille (CEPCM)</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 91 38 84 77</phone>
    </contact>
    <investigator>
      <last_name>Fabrice Barlesi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut régional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+33 4 67 61 25 15</phone>
    </contact>
    <investigator>
      <last_name>Xavier Quantin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 2 53 48 27 27</phone>
    </contact>
    <investigator>
      <last_name>Jafaar Bennouna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 2 99 28 99 59</phone>
    </contact>
    <investigator>
      <last_name>Hervé Léna</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Franlkfurt</name>
      <address>
        <city>Frankfurt am main</city>
        <zip>60385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Sebastian, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken der Stadt Köln GmbH</name>
      <address>
        <city>Köln</city>
        <zip>51067</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica Jürgens, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.pdc-line-pharma.com/</url>
    <description>PDC*line Pharma website</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 17, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

